Stereotaxis Reports Fourth Quarter and Full Year 2007 Financi...(hmias and our emerging participation in ...)

Date:3/3/2008

hmias and our emerging participation in the treatment of cardiovascular and peripheral vascular disease," said Bevil Hogg, Chief Executive Officer of Stereotaxis. "While our growth in 2007 was impacted by the lack of availability of a magnetic irrigated catheter, more than 6,000 procedures were performed during the past year using the Stereotaxis Niobe system across an average installed base of approximately 60 systems. We are very confident that in 2008 our average installed base will be approximately 100 systems and that the number of non-irrigated catheter cases will continue to grow accordingly. With regulatory approvals in Europe and the U.S. for our partnered magnetic irrigated catheter behind us, we can prepare to fill the demand expressed by clinicians and leading hospitals worldwide who are very interested in the possibilities offered by this catheter in combination with our Niobe system."

"We are continuing to bring innovative solutions to the market," continued Mr. Hogg. "This innovation centers on simplifying complex procedures while enhancing procedure efficacy and both patient and doctor safety. During 2008, we expect to introduce at the Heart Rhythm Society conference major transformative software that will substantially improve the simplicity and efficacy of our Niobe system user interface and enhance our automation of procedure work flows. In addition, we are in strategic discussions with a number of major industry participants regarding the partnering of our Odyssey information management and networking system in order to extend its reach beyond the Niobe installed base. We believe that Odyssey has the potential to become the information management backbone for the interventional laboratory and that this potential extends far beyond the Niobe market opportunity. Meanwhile, we continue to build interest, and orders, for Odyssey within our existing cath lab market and are optimistic about its prospects for 2008.

"With the full commercia
'/>"/>

SOURCE Stereotaxis, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Genetic Engineering & Biotechnology News reports on advances in miRNA
5. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. Cepheid Reports Fourth Quarter and Full Year 2007 Results
8. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
9. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
10. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
11. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results